Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier.

Authors: Hosokawa, T  Nakajima, H  Doi, Y  Sugino, M  Kimura, F  Hanafusa, T  Takahashi, T 
Citation: Hosokawa T, etal., J Neuroimmunol. 2011 Jul;236(1-2):81-6. doi: 10.1016/j.jneuroim.2011.04.009. Epub 2011 May 31.
Pubmed: (View Article at PubMed) PMID:21621856
DOI: Full-text: DOI:10.1016/j.jneuroim.2011.04.009

Matrix metalloproteinase-9 (MMP-9) plays an important role in some neuroinflammatory diseases through the blood-brain barrier (BBB) disruption. To investigate the pathogenicity of MMP-9 in neuromyelitis optica (NMO), serum and CSF MMP-9 concentrations were measured in 13 NMO and 15 multiple sclerosis (MS) patients and 14 healthy controls, and correlated with clinical and laboratorial parameters. Serum MMP-9 concentrations were significantly higher in NMO than MS and controls, and correlated with EDSS score, CSF/serum albumin ratio, and CSF IL-8 concentrations. Our results indicate that MMP-9, promoted by elevated IL-8 activation, plays a crucial role in the pathogenesis of NMO through the BBB disruption.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 8547883
Created: 2014-02-27
Species: All species
Last Modified: 2014-02-27
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.